We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hyperglycemia and (Pre)Diabetes in Pediatric Renal and Liver Transplantation. (DIAB-GRAFT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05464043
Recruitment Status : Completed
First Posted : July 19, 2022
Last Update Posted : August 11, 2022
Sponsor:
Information provided by (Responsible Party):
Université Catholique de Louvain

Brief Summary:

Background: Diabetes is a common complication of transplantation and is associated with unfavorable medical outcome and increased cardiovascular disease at long term. However, prediabetes defined by an impaired glucose tolerance and/or impaired fasting glucose is rarely sought in pediatric liver (LT) and renal (RT) transplantation, while its presence indicates a high risk of overt diabetes and complications thereof. Early detection of hyperglycemia might mitigate those risks. The objectives of the DIABGRAFT study were to retrospectively (rDIABGRAFT) and longitudinally (pDIABGRAFT) characterize hyperglycemia and (pre)diabetes in a cohort of children with RT or/and LT.

Methods: The investigators retrospectively collected data about 195 children with LT from 2012 and 2019 and twenty children with RT from 2005 to 2019 in Cliniques universitaires Saint Luc to determine the incidence, risk factors and time at onset of chronic hyperglycemia. In addition, the investigators prospectively followed four LT and four RT children between 2019 and 2022 to evaluate the evolution of their glucose metabolism.


Condition or disease Intervention/treatment Phase
Diabetes Mellitus Risk Diagnostic Test: evaluation of second line glucose homeostasis Not Applicable

Detailed Description:

BACKGROUND/AIM: Solid organ transplantation (SOT) is therapeutic choice for patient in end-stage renal or liver disease. After transplant, immunosuppressive therapy is necessary to avoid rejection and their use has enabled SOT and considerably improved graft survival and quality of life. However, they are also associated with side effects, including glycemic abnormalities. Most complications observed with immunosuppressants are the presence of hyperglycemia which in the long term may increase the probabilities to develop persistent diabetes. Diabetes affects an ill-defined proportion of transplanted patients (2 to 53%) and in the context of adult liver and renal transplant, it is nonetheless common, and represents approximately 20%. However, the incidence of transient hyperglycemia and the probabilities to develop overt diabetes in pediatric liver and renal transplantation remains unknow, while it is known that both is associated with an unfavorable prognosis (i.e., mortality, graft rejection, increased hospital stay) and an increased cardiovascular event in the long term. Moreover, associated risk factors such as obesity, metabolic syndrome, sedentary lifestyle, or even older age are well known for adult transplant but do not make sense for children transplanted at a very young age. In addition, the use of a non-relevant measure such as fasting blood glucose and a late-onset diabetes marker like HbA1C levels do not allow the early detection of impaired glucose tolerance (IGT) a signal alarm of a prediabetes state. Prediabetes is considered as an intermediate state between normal glucose homeostasis and overt diabetes and represents a major health problem because it is estimated in 2015 that 70% of the prediabetic American citizens (33,5%) will develop diabetes in the period. However, it is rarely sought in pediatric transplantation while the early detection and correction of hyperglycemia was shown to significantly decrease both cardiovascular and diabetes risk. It is therefore essential to develop knowledge on the evolution of glucose dysregulation after a renal and liver transplantation with the implementation of other markers of hyperglycemia or IGT. Then the purpose of the DIABGRAFT study was to assess the incidence and associated risk factors of developing hyperglycemia in renal and liver transplanted children to anticipate it and analyze their glycemic profile during the most critical moment to characterize hyperglycemia, IGT and diabetes.

METHODS: In collaboration with the Pediatric Gastroenterology and Specialized Pediatrics Services (Endocrinology and Nephrology Units) of Cliniques universitaires Saint Luc (CUSL) in Belgium (Brussels), this clinical study will be organized as a retrospective and a prospective trial.

The study included liver and renal transplanted pediatric patients (<18 years of age) at CUSL. Were excluded patients with a history of diabetes (i.e., type 1, type 2, neonatal or monogenic), pancreatitis, Down Syndrome, cystic fibrosis, another transplantation (cardiac, renal) only for liver transplanted patients, patients deceased shortly after transplantation, and patients with incomplete medical record.

Its retrospective part (rDIABGRAFT) consisted of collecting data of pediatric patients who benefited from a liver transplant performed at CUSL between April 2012 and April 2019, or that benefited from a renal transplant in our center between April 2005 and April 2019.

The prospective part (pDIABGRAFT) of the study consisted of a longitudinal glycemic evaluation of renal and liver transplanted children in CUSL between 2020 and 2022 with the use of dynamic endocrine testing. Informed consents were collected from parents and from all children over six years of age.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Screening for Diabetes and Pre-diabetes in a Cohort of Pediatric Patients Who Have Received a Liver or Kidney Transplant (DIAB-GRAFT)
Actual Study Start Date : June 20, 2019
Actual Primary Completion Date : December 31, 2019
Actual Study Completion Date : April 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: diabetic cohort

Patients who receive liver or kidney transplants and immunosuppressive drugs with diabetogenic risk.

After 14 days of immunosuppressive therapy, all admitted patients will be evaluated for first-line glucose homeostasis. This patient cohort will be referred to as the "diabetes risk cohort".

Subjects will then be stratified into two groups of patients: those who have developed glycemic dysregulation or diabetes during immunosuppressive therapy, the "diabetic cohort", and those who have not developed glycemic dysregulation or diabetes, the "control cohort". Only those who have developed glycemic dysregulation or diabetes during immunosuppressive therapy, i.e. the "diabetic cohort", will be analysed in more detail with the evaluation of second-line glucose homeostasis at three different times.

Diagnostic Test: evaluation of second line glucose homeostasis
blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires




Primary Outcome Measures :
  1. Retrospective study: characterization of hyperglycemia and diabetes after liver or kidney transplantation [ Time Frame: Before transplantation until the end of the study (April 2022) ]
    Incidence and risk factors of hyperglycemia and diabetes after liver or kidney transplantation


Secondary Outcome Measures :
  1. Prospective: analysis of impaired glucose tolerance (prediabetes) and diabetes after liver or kidney transplantation [ Time Frame: At day 14 post transplantation until 1 month for liver transplant and 9 months for kidney transplant ]
    Composite of tests and analysis to evaluate glucose homeostasis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who have undergone liver and/or kidney transplantation and immunosuppressive treatments such as glucocorticoids, cyclosporin A, tacrolimus and sirolimus, treated and monitored in the gastroenterology and pediatric hepatology department and in the pediatric nephrology department (hospitalized patients and outpatient clinics) of Cliniques universitaires Saint-Luc.
  • Informed consent obtained prior to any activity related to the trial. Test activities are all procedures performed as part of the test, including activities to determine test suitability.
  • Age of the patient at presentation: 2 years - 18 years.
  • For inclusion in the diabetogenic risk cohort: patients under diabetogenic treatment protocols such as glucocorticoids, cyclosporin A and tacrolimus.
  • For inclusion in the diabetic cohort: patients under diabetogenic treatment protocols such as glucocorticoids, cyclosporin A and tacrolimus and diabetes diagnosis according to the 2014 guidelines of the International Paediatric and Adolescent Diabetes Society (ISPAD).

Exclusion Criteria:

Diagnosis of type 1 or monogenic diabetes; Palliative care patients; History of pancreatitis (acute or chronic);


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05464043


Locations
Layout table for location information
Belgium
Cliniques Universitaires Saint-Luc - UCLouvain
Brussel, Belgium, 1200
Sponsors and Collaborators
Université Catholique de Louvain
Investigators
Layout table for investigator information
Principal Investigator: Philippe Lysy, MD, Phd Cliniques Universitaires Saint-Luc UCLouvain
Layout table for additonal information
Responsible Party: Université Catholique de Louvain
ClinicalTrials.gov Identifier: NCT05464043    
Other Study ID Numbers: DIAB-GRAFT
First Posted: July 19, 2022    Key Record Dates
Last Update Posted: August 11, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases